• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth

    5/16/26 11:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email

    Lilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebration

    INDIANAPOLIS, May 16, 2026 /PRNewswire/ -- The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE:LLY) and Musco Lighting, has opened three new multi-sport community courts across Indianapolis—creating year-round access to safe, high-quality spaces for youth to play. These latest court openings include two courts at Indianapolis Public Schools—Clarence Farrington and Edison School of the Arts—and a public court at the corner of E. South Street and S. New Jersey Street, that Lilly will provide to the City of Indianapolis and Indy Parks as part of its 150th anniversary celebration.

    Caitlin Clark, founder of the Foundation and advocate for youth access to sport, has been closely involved in the vision behind Community Courts and its expansion into Indianapolis. "I grew up playing a lot of different sports, and some of my favorite memories are just being outside with my friends and brothers, competing and having fun," said Caitlin Clark. "That's where so much growth happens. These courts give kids in Indianapolis a place to do that every day, and I'm thankful to Lilly and Musco for helping make it possible."

    "Caitlin has always believed in the power of sport to shape confidence, discipline, and opportunity," said Mary Coffin, President of the Caitlin Clark Foundation. "These courts give more young people a place to build those foundations together in their communities."

    As part of its 150th anniversary, Lilly is providing the park and court at the corner of E. South Street and S. New Jersey Street to the City of Indianapolis and Indy Parks, reinforcing its longstanding connection to the community and commitment to investing in spaces where people live, play and gather.

    "Health is shaped not only by medicine, but by the spaces and opportunities that help people stay active and connected," said Melissa Coe, Associate Vice President, Social Impact & Community Engagement at Lilly. "Through our partnership with the Caitlin Clark Foundation, we're proud to help create places across Indianapolis where young people and families can come together, move and build healthy habits that last."

    "Indy Parks is deeply grateful for the generosity of Lilly and the Caitlin Clark Foundation," said Indy Parks Director Brittany Crone. "The new park will be a vibrant and inspiring spot that encourages us to slow down and play together right in the heart of our downtown." 

    The court at the corner of E. South Street and S. New Jersey Street will remain open to the public as a free, accessible space maintained by Indy Parks and Recreation, while the IPS courts will support students through school programming—ensuring these spaces serve as lasting resources for the community. Built using the Musco Mini-Pitch System™, the courts are designed for basketball, soccer, and futsal, and include lighting, and ADA-accessible features—creating flexible, inclusive spaces for a wide range of users.

    "Every kid and every family deserves a place where they can connect with their community—and that's exactly what these community courts are bringing to Indianapolis," said Jeff Rogers, CEO of Musco. "We commend our partners at the Caitlin Clark Foundation and at Lilly. This is going to impact a lot of lives for many years."

    About Lilly

    Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY

     

    About Caitlin Clark Foundation

    The Caitlin Clark Foundation is dedicated to uplifting and improving the lives of youth and their communities through education, nutrition, and sport—the pillars that shaped Caitlin's own journey. Through initiatives like Community Courts, the Foundation creates opportunities for young people to grow, compete, and thrive. Learn more at www.caitlinclarkfoundation.org.

    About Musco Lighting

    For 50 years, Musco has been the world leader in sports lighting and facility solutions, providing innovative solutions for projects in more than 135 countries. Musco Lighting solutions are found on neighborhood fields, major stadiums and arenas, international airports, rail yards, the Olympic Games, iconic landmarks, and some of the world's largest ports. Musco has installed over 450 mini-pitches in the U.S. and is collaborating with the U.S. Soccer Foundation to bring 1,000 mini-pitches to the U.S. by the 2026 FIFA World Cup. For more information, visit www.musco.com/mini-pitch/.

    Trademarks and Trade Names

    All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

    Refer to:

    Jessica Thompson; thompson_jessica@lilly.com; 317-499-2042 (Lilly)



    Mary Coffin; mary.coffin@caitlinclarkfoundation.org (Caitlin Clark Foundation)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-caitlin-clark-foundation-and-musco-lighting-open-three-community-sports-courts-in-indianapolis-expanding-year-round-access-for-youth-302774000.html

    SOURCE Eli Lilly and Company

    Get the next $LLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    2/20/2026$1350.00Overweight
    Barclays
    1/7/2026$1250.00Buy
    UBS
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    More analyst ratings

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:19:57 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,851 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:18:50 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,280 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:17:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

    Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapyNew analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopausePivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complicationsINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide

    5/28/26 1:00:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foundayo and Zepbound now covered for millions of Americans

    CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicineINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance."For too long, effective obesity treatment has been out of reach for the people who need it," said Ilya Yuffa, executive vice president and president of Lilly USA and global cust

    5/28/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    SEC Filings

    View All

    SEC Form 8-K filed by Eli Lilly and Company

    8-K - ELI LILLY & Co (0000059478) (Filer)

    5/20/26 4:30:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Eli Lilly and Company

    SD - ELI LILLY & Co (0000059478) (Filer)

    5/11/26 4:30:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ELI LILLY & Co (0000059478) (Filer)

    5/7/26 4:41:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly declares second-quarter 2026 dividend

    INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock.The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to

    5/4/26 11:11:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

    Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound.Q1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a non-GAAP basis. The Q1 2026 reported and non-GAAP EPS included $0.52 of acquired IPR&D charges compared to $1.72 in Q1 2025.Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.Regulatory progress included U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Pipeline progres

    4/30/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care